Chemical Property of Indacaterol Maleate
Chemical Property:
- Appearance/Colour:White Solid
- Melting Point:195-197°C (dec.)
- PSA：160.21000
- LogP:3.66390
- Storage Temp.:Refrigerator
- Solubility.:DMSO (Slightly), Methanol (Slightly)
- Hydrogen Bond Donor Count:6
- Hydrogen Bond Acceptor Count:8
- Rotatable Bond Count:8
- Exact Mass:508.22095136
- Heavy Atom Count:37
- Complexity:708
- Purity/Quality:
-
99% *data from raw suppliers
IndacaterolMaleicAcidSalt *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Useful:
- Canonical SMILES:CCC1=C(C=C2CC(CC2=C1)NCC(C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC.C(=CC(=O)O)C(=O)O
- Isomeric SMILES:CCC1=C(C=C2CC(CC2=C1)NC[C@@H](C3=C4C=CC(=O)NC4=C(C=C3)O)O)CC.C(=C\C(=O)O)\C(=O)O
- Recent ClinicalTrials:Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
- Recent EU Clinical Trials:Comparison of 1-year treatment with inhaled long acting bronchodilators (LABD) plus inhaled glucocorticosteroids (ICS) versus LABD without ICS on re-hospitalizations and/or death in elderly patients with chronic obstructive pulmonary disease (COPD) recently hospitalized because of an acute exacerbation of COPD (ICS-Life study).
- Recent NIPH Clinical Trials:Safety of LAMA/LABA combination therapy in the COPD patients
-
Uses
A long-acting β2 adrenoreceptor agonist and bronchodilator, for the treatment of asthma and chronic obstructive pulmonary disease.
-
Clinical Use
Indacaterol is a b-adrenoceptor agonist currently approved in
Europe as Onbrez, and is marketed by Novartis. It needs to be
taken only once a day, unlike competitors formoterol and salmeterol.
These drugs are used in the treatment of chronic obstructive
pulmonary disease (COPD) and asthma. Onbrez is administered via
an aerosol formulation through a dry powder inhaler. A Phase III
trial published in July 2010 suggested that indacaterol is significantly
more effective than twice-daily formoterol in improving
FEV1 and reduces the need for rescue medication.
